Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects. 1984

R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache

The effects of diazepam (10-160 mg) and oxazepam (30-480 mg) were studied in volunteers with histories of drug abuse. Oral doses were administered every third day under double-blind and counterbalanced conditions. Dose-effects with area under the time-action curve data (AUC) showed diazepam to be 2.6-5.7-times more potent than oxazepam on various psychomotor, cognitive, staff-rated, and subjective measures. Comparison of relative potencies showed diazepam to be relatively more potent in producing 'liking' than in producing psychomotor and cognitive effects. Diazepam produced greater peak effects than oxazepam on a number of staff- and subject-rated measures, including liking. Onset of effect was more rapid and time to maximal effect was shorter (1-2 h versus 4-12 h) with diazepam than oxazepam, while time to offset of effect was similar for the two drugs. Diazepam was categorized as producing barbiturate-like subjective effects (38.3%) more frequently than was oxazepam (13.8%), while oxazepam was identified as placebo more often than diazepam. Repeated administration of 160 mg diazepam and 480 mg oxazepam showed that AUC liking was greater for diazepam than oxazepam and that tolerance to psychomotor and cognitive effects occurred with oxazepam but not diazepam. This study suggests that diazepam may have a higher abuse liability than oxazepam.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010076 Oxazepam A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia. Adumbran,Serax,Tazepam
D011597 Psychomotor Performance The coordination of a sensory or ideational (cognitive) process and a motor activity. Perceptual Motor Performance,Sensory Motor Performance,Visual Motor Coordination,Coordination, Visual Motor,Coordinations, Visual Motor,Motor Coordination, Visual,Motor Coordinations, Visual,Motor Performance, Perceptual,Motor Performance, Sensory,Motor Performances, Perceptual,Motor Performances, Sensory,Perceptual Motor Performances,Performance, Perceptual Motor,Performance, Psychomotor,Performance, Sensory Motor,Performances, Perceptual Motor,Performances, Psychomotor,Performances, Sensory Motor,Psychomotor Performances,Sensory Motor Performances,Visual Motor Coordinations
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D003975 Diazepam A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity. 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one,Apaurin,Diazemuls,Faustan,Relanium,Seduxen,Sibazon,Stesolid,Valium
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004644 Emotions Those affective states which can be experienced and have arousing and motivational properties. Feelings,Regret,Emotion,Feeling,Regrets
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
June 1993, Behavioural pharmacology,
R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
December 1990, The Journal of pharmacology and experimental therapeutics,
R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
August 1992, The Journal of pharmacology and experimental therapeutics,
R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
January 1978, Acta psychiatrica Scandinavica. Supplementum,
R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
December 1987, The Journal of pharmacology and experimental therapeutics,
R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
April 1987, Pharmacology, biochemistry, and behavior,
R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
February 1986, Drug and alcohol dependence,
R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
May 2014, Tobacco control,
R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
January 1986, Psychopharmacology,
R R Griffiths, and D R McLeod, and G E Bigelow, and I A Liebson, and J D Roache
August 2007, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!